The lancet. Psychiatry
-
The lancet. Psychiatry · May 2015
Randomized Controlled TrialD-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.
Antagonists of N-methyl-D-aspartate-type glutamate receptors (NMDAR) induce symptoms that closely resemble those of schizophrenia, including negative symptoms. D-serine is a naturally occurring NMDAR modulator that reverses the effects of NMDAR antagonists in animal models of schizophrenia. D-serine effects have been assessed previously for treatment of established schizophrenia, but not in the early stages of the disorder. We aimed to assess effects of D-serine on negative symptoms in at risk individuals. ⋯ National Institutes of Health.
-
The lancet. Psychiatry · May 2015
Substance use disorders, psychiatric disorders, and mortality after release from prison: a nationwide longitudinal cohort study.
High mortality rates have been reported in people released from prison compared with the general population. However, few studies have investigated potential risk factors associated with these high rates, especially psychiatric determinants. We aimed to investigate the association between psychiatric disorders and mortality in people released from prison in Sweden. ⋯ Wellcome Trust, Swedish Research Council, and the Swedish Research Council for Health, Working Life and Welfare.